Nebulized Furosemide for Coronavirus

Phase-Based Progress Estimates
Coronavirus+1 MoreNebulized Furosemide - Drug
18 - 100
All Sexes
What conditions do you have?

Study Summary

This trial will study the effects of nebulized furosemide on pulmonary inflammation in patients with COVID-19 who are intubated and on mechanical ventilation.

Eligible Conditions
  • Coronavirus
  • Respiratory Failure

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: Day 60 post enrollment

Baseline to day 28
Requirement for mechanical ventilation
Day 60 post enrollment
Study Day 6
Improvement in pulmonary gas exchange
Day 28
Requirement for supplemental oxygen
Day 60
Adverse events
Duration of ICU Stay
Length of hospitalization
Up to day 28
Cytokine levels
Electrolyte abnormalities
Inhalation adverse events
Serum levels of furosemide

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Inhaled Furosemide
1 of 2
Nebulized Saline
1 of 2

Experimental Treatment

Non-Treatment Group

640 Total Participants · 2 Treatment Groups

Primary Treatment: Nebulized Furosemide · Has Placebo Group · Phase 2 & 3

Inhaled Furosemide
Experimental Group · 1 Intervention: Nebulized Furosemide · Intervention Types: Drug
Nebulized Saline
PlaceboComparator Group · 1 Intervention: Nebulized Saline · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 60 post enrollment

Who is running the clinical trial?

University Health Network, TorontoOTHER
1,382 Previous Clinical Trials
472,835 Total Patients Enrolled
Queen's UniversityLead Sponsor
336 Previous Clinical Trials
110,308 Total Patients Enrolled
John Muscedere, MDPrincipal InvestigatorQueens University
2 Previous Clinical Trials
2,020 Total Patients Enrolled

Eligibility Criteria

Age 18 - 100 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: